Johnson & Johnson 2025 Q2 Earnings Report: Dual Engines Accelerate Growth Against Headwinds

While the global pharmaceutical industry continues to struggle under the dual pressures of the "patent cliff" and "payer pricing controls," Johnson & Johnson (J&J) has issued an unexpectedly strong Q2 2025 earnings report that signals a different trajectory: steady revenue growth, healthy profitability expansion, and another upward revision to its full-year guidance. This healthcare giant, spanning both MedTech and Innovative Medicine, is proving through its "dual-engine" strategy that it can not only weather economic cycles—but accelerate through them.

Strong Performance Driven by Dual Engines

In Q2 2025, Johnson & Johnson achieved global sales of $23.7 billion, a year-over-year increase of 5.8%, or 4.6% on an operational basis (adjusted for currency). Diluted earnings per share (EPS) rose to $2.29, up 18.7% year-over-year, while adjusted diluted EPS came in at $2.77, a 1.8% increase. The Innovative Medicine segment reported global sales of $15.2 billion, up 4.9%, with operational growth of 3.8%. The MedTech segment recorded global sales of $8.5 billion, growing 7.3% year-over-year and 6.1% operationally.

Joaquin Duato, Chairman and CEO of Johnson & Johnson, stated: “Our outstanding second-quarter performance demonstrates the unique strength of our diversified portfolio across MedTech and Innovative Medicine. Our product pipeline and R&D programs provide a strong foundation for accelerated growth in the second half of the year, with anticipated approvals and filings in areas such as lung cancer, bladder cancer, major depressive disorder, psoriasis, surgical innovations, and cardiovascular health.” He emphasized that these innovations are expected to significantly extend patient lifespans and improve quality of life.

Innovative Medicine Growth Led by Oncology and Neuroscience

J&J's Innovative Medicine segment delivered robust performance in Q2 2025 with $15.2 billion in global sales, marking a 4.9% increase year-over-year. Although the expiration of STELARA?'s patent negatively impacted results by 1,170 basis points, strong growth in oncology and neuroscience offset the loss.

Oncology stood out with $6.3 billion in sales—a 24% year-over-year increase—driven by rising market share for products like DARZALEX?, ERLEADA?, and CARVYKTI?. Neuroscience posted $2.0 billion in sales, up 15.1%, fueled by growing patient demand for SPRAVATO?. Infectious diseases generated $800 million in revenue, up 16.8% year-over-year. Meanwhile, the immunology segment brought in approximately $4.0 billion, a 15.4% decline primarily due to STELARA? facing biosimilar competition.

STELARA?, the world’s first biologic developed by J&J that selectively targets IL-12 and IL-23, is indicated for adult patients with moderate-to-severe Crohn’s disease (CD) who are unresponsive, lose response, or are intolerant to conventional therapy or TNFα inhibitors. From 2020 to 2024, STELARA? saw continuous hospital sales growth in China, surpassing ￥1 billion in 2024.

Rapid Growth in MedTech, With Cardiovascular Leading the Way

Johnson & Johnson’s MedTech business saw strong growth in Q2 2025, rising 7.3% year-over-year, driven by excellent performance in the cardiovascular segment, effective commercial strategies, and continued innovation. Global sales reached $8.541 billion, with cardiovascular sales contributing $2.313 billion—an impressive 23.5% increase, thanks to competitive advantages in electrophysiology and new product launches (such as VARIPULSE, TRPULSE, NUVISION, and QDOT).

Orthopedics recorded $2.305 billion in sales, a slight decline of 0.3%, impacted by volume-based procurement (VBP) policies in China affecting hip, knee, and spine segments. Surgical sales were $2.555 billion, up 2.7% year-over-year. Vision care generated $1.269 billion in revenue, growing 6.5%, with the ACUVUE OASYS 1-Day series driving strong performance in contact lenses.

Johnson & Johnson’s strong performance in Q2 2025 reaffirms its industry leadership and resilience amid ongoing challenges in the healthcare sector. Despite patent expirations in innovative pharmaceuticals, the company has made breakthrough progress in oncology and neuroscience, providing solid momentum for future growth. The rapid advancement of its MedTech segment—especially in cardiovascular innovation—further strengthens its global competitiveness.

Looking ahead, J&J’s diversified product portfolio and robust R&D pipeline position it to achieve major breakthroughs across more therapeutic areas. It is well-poised to drive continued innovation in healthcare technology, bringing renewed hope and improved quality of life to patients around the world.

Reference

[1]. https://s203.q4cdn.com/636242992/files/doc_financials/2025/q2/Final-JNJ-Earnings-Presentation-Q2-2025-Webcast.pdf